.2% of Candida isolates tested were susceptible (S) to fluconazole; however, 13 of 31 species identified exhibited decreased susceptibility (<75% S), similar to that seen with the resistant (R) species C. glabrata and C. krusei. Among 197,619 isolates of Candida spp. tested against voriconazole, 95.0% were S and 3% were R. About 30% of fluconazole-R isolates of C. albicans, C. glabrata, C. tropicalis, C. rugosa, C. lipolytica, C. pelliculosa, C. apicola, C. haemulonii, C. humicola, C. lambica, and C. ciferrii remained S to voriconazole. An increase in fluconazole resistance over time was seen with C. parapsilosis, C. guilliermondii, C. lusitaniae, C. sake, and C. pelliculosa. Among the emerging fluconazole-R species were C. guilliermondii (11.4% R), C. inconspicua (53.2% R), C. rugosa (41.8% R), and C. norvegensis (40.7% R). The rates of isolation of C. rugosa, C. inconspicua, and C. norvegensis increased by 5-to 10-fold over the 10.5-year study period. C. guilliermondii and C. rugosa were most prominent in Latin America, whereas C. inconspicua and C. norvegensis were most common in Eastern European countries. This survey identifies several less-common species of Candida with decreased susceptibility to azoles. These organisms may pose a future threat to optimal antifungal therapy and underscore the importance of prompt and accurate species identification and antifungal susceptibility testing.
Antifungal susceptibility testing is playing an increasing role as a means to track the development of antifungal resistance in epidemiological studies (2, 10, 12, 17, 27, 45-47, 55, 63) . One of the important by-products of the standardization of antifungal susceptibility testing has been the ability to conduct surveillance for antifungal resistance using uniform methods (44) . Meaningful large-scale surveys of antifungal susceptibility and resistance conducted over time would not be possible without a standardized broth microdilution (BMD) or disk diffusion (DD) method for performing the in vitro studies (12, 38, 60) . Global surveillance programs such as the ARTEMIS antifungal surveillance program for DD testing (49, 57, 60) and MIC testing (12, 13) , the European Confederation of Medical Mycology (ECMM) survey of candidemia (68) , and the SENTRY Antifungal Surveillance Program (36) (37) (38) promote the use of standardized DD and BMD methods and provide useful and consistent antifungal susceptibility data from a broad international network of hospitals and laboratories.
The ARTEMIS global antifungal surveillance program is among the most comprehensive and long-running fungal surveillance programs (12, 45, 57, 58, 60) . The ARTEMIS program was designed to address many of the potential limitations of resistance surveillance studies (26) : (i) it is both longitudinal (1997 to present) and global (142 participating sites in 41 countries) in scope, (ii) it employs standardized DD (7) and BMD (9) antifungal susceptibility test methods, (iii) both internal quality control (QC) performed in each participating laboratory and external quality assurance measures are used to validate test results (48, 50, 61) , (iv) results are recorded electronically using the Biomic image analysis plate reader (Giles Scientific, Santa Barbara, CA) and are stored in a central database, and (v) both Candida and non-Candida (60) yeast isolates obtained from consecutive clinical samples from all body sites are tested locally, thus avoiding misleading results based on biased selective testing. Thus, the ARTEMIS program generates massive amounts of data that have been externally validated and that can be used to identify temporal and geographic trends in the species distribution of Candida and other opportunistic yeasts, as well as the resistance profiles of These isolates were obtained from 133 institutions during the period from 2001 through 2007. The percentages of isolates in each category (S, SDD, and R) were 90.2%, 3.6%, and 6.2% and 95.0%, 2.0%, and 3.0% for fluconazole and voriconazole, respectively. Fluconazole was most active (Ͼ90% S) against C. albicans (98.0% S), C. tropicalis (91.0% S), C. parapsilosis (93.2% S), C. lusitaniae (92.1% S), C. kefyr (96.5% S), C. dubliniensis (96.1% S), C. apicola (98.2% S), C. intermedia (95.8% S), C. pulcherrima (100% S), C. colliculosa (100% S), C. holmii (100% S), and C. sphaerica (100% S). Decreased sus- ceptibility to fluconazole (Ͻ75% S) was seen with C. glabrata (68.7% S), C. krusei (8.6% S), C. guilliermondii (73.5% S), C. inconspicua (22.6% S), C. rugosa (49.9% S), C. norvegensis (41.9% S), C. valida (23.8% S), C. humicola (50% S), C. lambica (0% S), C. ciferrii (50% S), and C. marina (0% S). Thus, despite the fact that overall 90% of all clinical isolates of Candida were susceptible to fluconazole, these data demonstrate that 13 of the 31 species identified in this survey exhibit decreased susceptibility on the order of that seen with the well-known resistant species C. glabrata and C. krusei. As noted previously (57), voriconazole was more active than fluconazole against most species of Candida with the exception of C. tropicalis (91.0% S to fluconazole versus 89.5% S to voriconazole); C. apicola (98.2% S to both); C. pulcherrima (100% S to both); C. haemulonii (88.9% S to both); C. stellatoidea (85.7% S to both); C. humicola (50% S to both); C. ciferrii (50% S to both); and C. colliculosa, C. holmii, and C. sphaerica (100% S to both). C. rugosa (69.3% S to voriconazole), C. lipolytica (77.3% S), C. humicola (50% S), C. lambica (40% S), and C. ciferrii (50% S) were all considerably less susceptible to voriconazole than were all other species of Candida.
A total of 12,179 isolates encompassing 24 different species of Candida were found to be resistant to fluconazole ( (1, 32, 42, 43, 57, 65, 66) . Trends in resistance to fluconazole among Candida spp. over a 10.5-year period. There was no consistent trend toward increasing resistance to fluconazole detected among the common species C. albicans, C. glabrata, and C. tropicalis over the 10.5-year time period (Table 5) . Likewise, consistently high levels of resistance were seen among C. krusei, C. inconspicua, C. norvegensis, and C. valida. Resistance was high among C. A slight increase in fluconazole resistance was noted among C. parapsilosis (2.5% to 3.6%), C guilliermondii (9.9% to 14.2%), and C. lusitaniae (2.9% to 6.0%) over the 10.5-year period. Although the numbers of isolates were small, C. saki (10.0% to 11.9%), C. pelliculosa (15.0%), C. haemulonii (33.3%) C. humicola (50%), C. lambica (80%), and C. ciferrii (50%) all showed elevated rates of resistance over the (Table  6 ). As noted previously (Table 3 ), resistance to voriconazole was uncommon (Ͻ5%) during each of the study years; however, a trend toward increased resistance over the most recent 3 years (2005 to 2007) was observed for C. famata (1.1% to 5.7%), C. norvegensis (0.0% to 6.9%), C. lipolytica (0.0% to 11.1%), and C. pelliculosa (14.3% to 16.7%). Notably, there was no trend toward increased resistance to voriconazole among the fluconazole-resistant species C. glabrata, C. krusei, C. guilliermondii, C. rugosa, and C. inconspicua.
Geographic variation in the susceptibilities of Candida to fluconazole and voriconazole. Table 7 presents the in vitro susceptibility results for fluconazole and voriconazole tested against the five most common species of Candida (C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei) and four uncommon fluconazole-resistant species (C. guilliermondii, C. inconspicua, C. rugosa, and C. norvegensis) stratified by geographic region for the time period from 2001 to 2007. Just as geographic variation was seen in the frequency of isolation of these different species (Table 2) , considerable variation in the frequency of azole resistance was observed as well. Although both fluconazole and voriconazole were highly active against C. albicans in all geographic regions, considerably higher rates of resistance to both azoles were detected among isolates from North America than among those from the other four regions. Similarly to C. albicans, the highest rates of azole resistance among isolates of C. glabrata were seen in North America.
C. tropicalis is now recognized as the second most common species of Candida isolated from patients with invasive candidiasis in the Asia-Pacific region (5, 23, 28, (70) (71) (72) (73) (74) (75) (Table 2) . Reports from Taiwan have also highlighted the emergence of fluconazole resistance in C. tropicalis from a variety of different specimen types (71, 74) . These findings are supported by the most recent ARTEMIS data, where the highest rates of resistance to both fluconazole and voriconazole were seen among isolates of C. tropicalis from the Asia-Pacific region ( Table 7 ). The lowest rates of resistance to both azoles were seen with isolates of C. tropicalis from the Africa/Middle East region. As noted previously (57), C. tropicalis isolates from all regions, with the exception of those from the Africa/Middle East region, were slightly more resistant to voriconazole than to fluconazole.
Azole resistance among isolates of C. parapsilosis is generally considered to be infrequent (59, 69) , and that is the case in all of the regions surveyed in the ARTEMIS program with the exception of those isolates from the Africa/Middle East region (Table 7) . Whereas resistance to fluconazole and voriconazole was Ͻ5% and Ͻ3%, respectively, in Europe, Latin America, North America, and the Asia-Pacific regions, it was 15.0% and 11.1%, respectively, in the Africa/Middle East region, with the highest rates seen in isolates from South Africa (21% and 15%, respectively).
Among the five species of Candida that are recognized as having decreased susceptibility to fluconazole, C. krusei showed high-level resistance in all of the geographic regions. Interestingly, 14% of isolates of C. krusei from Latin America were resistant to voriconazole compared to only 4.5% to 7.7% of isolates from other regions.
Isolates of C. guilliermondii from the Asia-Pacific region and Europe were more resistant to both fluconazole and voriconazole than were those from other regions, whereas the highest rates of resistance to both agents among C. rugosa isolates were seen in Latin America. The greatest geographic variation in resistance to voriconazole was noted with C. rugosa, where 32.8% of Latin American isolates were resistant compared to 0% to 11.1% in the other regions.
Both C. inconspicua and C. norvegensis appear predominately in Europe, and isolates of both species from this region demonstrate a fluconazole-resistant and voriconazole-susceptible phenotype. Whereas the few isolates of C. inconspicua from other regions also exhibit this phenotype, isolates of C. norvegensis from regions other than Europe are generally susceptible to both azoles. Variation in the frequency of isolation and the antifungal susceptibility profile of C. krusei, C. inconspicua, and C. norvegensis by clinical service. C. krusei, C. inconspicua, and C. norvegensis are uncommon species of Candida that share a fluconazole-resistant, voriconazole-susceptible phenotype (3, 11, 14, 34, 62) . Although C. krusei is well studied, little is known of the frequency of occurrence and variation in azole susceptibility of C. inconspicua and C. norvegensis according to clinical service (3, 11, 18, 58, 62) . The clinical services reporting the isolation of those three species from patient specimens included the hematology-oncology service, medical and surgical services, intensive care units (ICUs; medical-surgical and neonatal), the dermatology service, the urology service, and the outpatient service (Table 8) . Those strains from services with only a few isolates and those for which a clinical service was not specified were included in the category "other, not otherwise specified" (other, NOS).
C. krusei was isolated most frequently from the hematologyoncology service and the medical service. Whereas resistance to fluconazole was elevated in every service, resistance to voriconazole was Ͻ10% in all services except the neonatal ICU (13.8% [data not shown]) and the outpatient service (10.1%).
Less than 80% of isolates from the hematology-oncology and dermatology services were susceptible to voriconazole.
As with C. krusei, C. inconspicua was isolated most frequently from the hematology-oncology and medical services. Previously, D'Antonio et al. (11) reported a cluster of catheterrelated infections due to C. inconspicua in patients with hematologic malignancies. More than 50% of isolates from the hematology-oncology, surgical, ICU, and dermatology services were resistant to fluconazole, whereas less than 6% of isolates from all services except dermatology (only 4 isolates tested) were resistant to voriconazole.
C. norvegensis has been reported as a cause of invasive candidiasis among immunosuppressed patients in Denmark and Norway (62) . This species was isolated most frequently from patients on the medical service, and more than 30% of isolates from all services except the surgical and dermatology services were resistant to fluconazole. By comparison, resistance to voriconazole was uncommon (0% to 4.2%) in all services except for the urology service (1 of 6 isolates [16.7%]).
Variation in the frequency of isolation and the antifungal susceptibility profiles of C. krusei, C. inconspicua, and C. norvegensis by clinical specimen type. The major specimen types (Table 8) . Those isolates from uncommon specimen types and those for which as specimen type was not recorded were grouped under "miscellaneous, NOS." C. krusei accounted for 2 to 3% (each) of all Candida spp. isolated from blood, NSBF, urine, respiratory tract, and skin and soft tissue specimens. It was isolated infrequently from genital specimens. Fluconazole resistance was apparent in Ͼ70% of isolates from all specimen types, whereas resistance to voriconazole ranged from 4.5% of isolates from NSBF to 11.4% of isolates from urine. Isolates from blood (86.3% S) and cerebrospinal fluid (100% S) were more likely to be susceptible (S) to voriconazole than were those from urine (76.4% S).
The majority of C. inconspicua isolates reported in the literature are from the respiratory tract; however, wound, blood, and genital isolates have also been obtained (3, 11, (33) (34) (35) . Whereas the previous reports concerning C. inconspicua contained no more than 50 clinical isolates, the present data set is considerably more robust and shows C. inconspicua isolated from numerous body sites, including blood and NSBF. Consistent with the literature, C. inconspicua was isolated most frequently from the respiratory tract.
Fluconazole resistance among isolates of C. inconspicua ranged from 26.1% for isolates from skin and soft tissue specimens to 62.9% from genital specimens. Half of all isolates from NSBF and more than a third of isolates from blood were resistant to fluconazole. Resistance (R) to voriconazole was less than 5% for isolates from all specimen types with the exception of isolates from urine (7.7% R) and miscellaneous specimen types (5.2% R).
C. norvegensis has been isolated from the oropharynx, blood, peritoneal fluid, urine, and a variety of deep tissue sites (22, 39, 40, 62, 67) . As with C. inconspicua, C. norvegensis was isolated most frequently from the respiratory tract and with approximately equal frequency from the other specimen types (Table  9 ). Whereas isolates from most specimen types were highly resistant to fluconazole (Ͼ40% R), isolates from blood (7.7% R) and skin and soft tissue (8.7% R) were considerably less resistant. Resistance to voriconazole was quite uncommon (0 to 1.6%) among isolates from all specimen types with the exception of those from urine (8.7% R) and miscellaneous specimen types (8.0% R). 
DISCUSSION
There is no lack of data concerning the in vitro susceptibility of isolates of C. albicans, C. glabrata, C. tropicalis, and C. parapsilosis to both fluconazole and voriconazole (24, 55) . Longitudinal surveillance studies from individual institutions, cities, countries, and broad geographic regions document the sustained activities of these agents versus C. albicans, C. tropicalis, and C. parapsilosis and the ongoing potential for C. glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63) . Using the ARTEMIS database, we have confirmed and extended these observations globally over a 10.5-year period of study.
These four major yeast pathogens vary in frequency of occurrence and azole susceptibility over the four geographic regions encompassed in this survey (Tables 2 and 7 ). Although C. albicans remains quite susceptible to both azoles, the data reported herein demonstrate a lower frequency of occurrence and yet a higher rate of resistance of this species to both fluconazole and voriconazole in North America compared to the other regions (Tables 2 and 7) . Likewise, C. glabrata remains more common in North America, and isolates from this region exhibit higher rates of azole resistance than do those from other parts of the world (Tables 2 and 7) . C. tropicalis is a prominent cause of invasive candidiasis in both the Latin American and Asia-Pacific regions (Table 2) . We have confirmed the earlier reports of increased resistance to fluconazole among isolates of C. tropicalis from the Asia-Pacific region (Table 7) (71, 74) . C. parapsilosis is well known as an exogenous cause of catheter-related fungemia (59, 69). Although resistance to fluconazole remains relatively uncommon (Table 3 ), there appears to be a slight trend toward increasing resistance over time (Table 5 ). Local outbreaks of C. parapsilosis fungemia document its role as a nosocomial pathogen (69) , and it is evident that when lapses in infection control precautions are coupled with broad use of fluconazole, an endemic, fluconazole-resistant strain of this species may emerge (6, 64) .
The present study extends the list of species of Candida that may be isolated from clinical specimens ( Table 1) . Although many of these species are uncommon, their appearance in this survey underscores an increased effort by clinical laboratories worldwide to identify isolates of Candida to the species level. One limitation of this survey is that most laboratories employed commercial identification methods that may have problems identifying the more unusual species (25). Previously we have been able to validate the identification of many of these species (47) , including cryptic species such as C. dubliniensis, C. metapsilosis, C. orthopsilosis, C. nivariensis, C. bracarensis, and C. fermentati (16, (29) (30) (31) . Unfortunately, with a survey of this magnitude we have been unable to do so in every case.
Despite the fact that 90% of the more than 250,000 isolates reported herein remain susceptible to fluconazole, it is important to realize that many of the less common species of Candida exhibit decreased susceptibilities to both fluconazole and voriconazole compared to those of C. albicans, C. tropicalis, and C. parapsilosis. Furthermore, despite the very potent activity and broad spectrum of activity shown by voriconazole (Table 3) , this agent is considerably less active against most (Table 4) . Thus, with few exceptions, Candida spp. causing infection in patients with previous fluconazole exposure are very likely to show decreased susceptibility to voriconazole as well (1, 32, 42) . This report highlights the few species that routinely express a fluconazole-resistant, voriconazole-susceptible phenotype (Tables 4 and 7 to 9). The most common of these, C. krusei, is well known, and studies have demonstrated that the voriconazole activity against this species may be attributed to enhanced binding of this triazole to the target enzyme compared to that of fluconazole (15, 56, 58) . Two additional species, C. inconspicua and C. norvegensis, share this fluconazole-resistant, voriconazole-susceptible phenotype (Tables 3 and 4) . Although quite uncommon in most regions of the world (Table   TABLE 8 2), these two species have been recognized for some time in Europe as fluconazole-resistant causes of candidal colonization and infection (3, 11, 14, 22, 34, 35, 39, 40, 62) . Among the isolates of C. krusei, C. inconspicua, and C. norvegensis in the present study, it is notable that they appear to be especially localized to Eastern Europe, namely, Hungary, Russia, and the Czech Republic. Whereas these three countries account for 21% of the Candida isolates overall, they account for 38% of all C. krusei, 31% of all C. norvegensis, and 75% of all C. inconspicua isolates (data not shown). European isolates of C. inconspicua and C. norvegensis appear to be more resistant to fluconazole than those from other geographic regions (Table  7 ). The epidemiological niche for these two species appears to be similar to that of C. krusei, with infection/colonization seen more frequently among patients housed in the hematologyoncology and medical services (Table 8 ). Whereas these species, as well as C. krusei, are often seen as colonizers (3, 22, 58, 62) , isolates from blood and NSBF are reported in this survey (Table 9 ) and in other reports in the literature (3, 11, 34, 35, 39, 40, 62) . These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66) . Given the ubiquitous use of azoles in prophylaxis and empirical and directed therapies (4, 43, 65, 66) , it is important to know the activities of the systemically active agents, such as fluconazole and voriconazole, against these organisms (65, 66) . The less common species of Candida often exhibit decreased susceptibility to fluconazole and, in some strains, to voriconazole (Table 3) ; this is important because these organisms may emerge as pathogens in immunocompromised patients who have already been receiving an azole (3, 11, 39, 41, 62, 65) . Whereas most species of Candida that exhibit acquired resistance to fluconazole also appear to be considerably less susceptible to voriconazole than their wild-type "fluconazolenaïve" counterparts (Table 4) , species such as C. krusei, C. inconspicua, and C. norvegensis may emerge during fluconazole therapy due to their intrinsic resistance to fluconazole and yet remain susceptible to voriconazole (Table 3 and 4) .
In summary, we have used the ARTEMIS database to provide further evidence of the sustained activity of fluconazole and voriconazole against a broad range of Candida species. With an ever-expanding array of species causing infection in highly compromised patients, it is important to understand the activity of these "workhorse" antifungal agents against both common and uncommon species. It is comforting to know that both of these triazoles remain active against many of the more common species; however, reduced activity of fluconazole may be seen among the less common species, and resistance to voriconazole is often encountered among species with acquired fluconazole resistance (Table 4) . Continued surveillance, both locally and on a regional and international basis, is clearly warranted.
Since it is a descriptive and sentinel-based study, there are certain limitations inherent in the ARTEMIS passive surveillance program that must be acknowledged. Despite a longstanding protocol for testing and reporting consecutive isolates from individual infectious episodes, there are no controls for participant compliance with the isolate submission protocol from one year to the next. This leads to the possibility that variations in the frequency of isolation of certain species may be influenced by financial, human resource, or policy changes and constraints and may under-or overestimate the true prevalence of any given species. Close monitoring of each study site's level of participation by the study coordinators using e-mail and other means of communication represents our efforts to ensure compliance with the data collection protocol. We recognize that studies of this scope are bound to have some variation in center participation, and we point out that the sheer number of submitted isolates from every region should help minimize individual center effects. Rigorous standardization of the CLSI disk diffusion method is ensured by both internal QC monitoring and external validation of both isolate identification and antifungal susceptibility results (29-31, 48, 50, 61) . Despite these limitations, the overall size of this collection of Candida isolates does provide useful descriptive information. Such information will continue to be useful as a basis for comparison for future studies regarding the prevalence and antifungal susceptibility of both common and uncommon species of Candida as agents of IC throughout the world.
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